Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
ADI members in the European and Caribbean regions took part in the first regional meetings of 2021 and since the COVID-19 pandemic began in early 2020.
As the 74th World Health Assembly begins, ADI is sharing a statement submitted to the World Health Organization (WHO) and Member States.
Davos Alzheimer's Collaborative (DAC) Co-chairs, Arnaud Bernaert and George Vradenburg, write about how DAC is building a coalition in order to accelerate Alzheimer's and dementia innovation.
ADI is pleased to welcome 6 new member associations, as well as new members to the ADI board.
During the 60-minute meeting, the advisory panel discussed ADI's activities over the last year, as well as proposals for future avenues of research, including a working group to explore the impact of COVID-19 as a potential risk factor for accelerating dementia.
The ADI Council met on 30 March 2021 to discuss ADI's activities over 2020, new membership applications and more.
The discussions focused on developing a regional policy brief for the promotion, protection and restoration of mental health in older adults, with the inclusion of a focus on dementia awareness and risk reduction.
Cohort Studies of Memory in an International Consortium